3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
4
Tumor-Agnostic
2
Sarcoma
1
Plasma cell
1
Lymphoid
1
CNS
1
Conditions
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Dexamethasone
124
daratumumab
73
Lenalidomide
72
Bortezomib
61
pomalidomide
45
Cyclophosphamide
41
carfilzomib
40
Calcium Dobesilate
36
Specimen Handling
34
Biopsy
30
Magnetic Resonance Spectroscopy
27
belantamab mafodotin
24
isatuximab
20
fludarabine
20
dexamethasone acetate
18
dexamethasone 21-phosphate
18
auricularum
18
Melphalan
18
talquetamab
16
iberdomide
16
fludarabine phosphate
12
selinexor
11
elotuzumab
10
X-Rays
10
tocilizumab
9
Nivolumab
8
Sirolimus
7
Crizotinib
7
trametinib
6
Whole-Body Irradiation
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
ceritinib
×
Plasma cell
×
90 days
×
Clear all
NCT05100134
2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available